Cryptococcosis, unspecified
ICD-10 B45.8 is a billable code used to indicate a diagnosis of cryptococcosis, unspecified.
Cryptococcosis is a fungal infection caused by the Cryptococcus species, primarily Cryptococcus neoformans and Cryptococcus gattii. This infection is particularly significant in immunocompromised patients, such as those with HIV/AIDS, organ transplant recipients, or individuals on immunosuppressive therapy. The fungus is typically acquired through inhalation of airborne spores found in soil, particularly in areas with bird droppings. Symptoms can range from mild respiratory issues to severe neurological complications, including meningitis. Diagnosis is often made through culture, serological tests, or imaging studies. Treatment typically involves antifungal medications such as amphotericin B and flucytosine, followed by maintenance therapy with fluconazole. The unspecified nature of this code indicates that the specific manifestation or site of infection is not documented, which can complicate treatment and management strategies.
Detailed patient history, laboratory results, and treatment plans.
Patients presenting with respiratory symptoms or meningitis in immunocompromised individuals.
Ensure documentation reflects the patient's immune status and any co-morbid conditions.
Pulmonary function tests, imaging studies, and treatment response.
Patients with respiratory distress or chronic cough with a history of exposure to potential sources of Cryptococcus.
Document any differential diagnoses and the rationale for antifungal therapy.
Used to confirm diagnosis in suspected cryptococcosis cases.
Document the reason for testing and results.
Infectious disease specialists should ensure comprehensive documentation of clinical findings.
Common symptoms include cough, fever, chest pain, headache, and altered mental status, particularly in immunocompromised patients.
Diagnosis is typically made through culture, serological tests for cryptococcal antigen, and imaging studies to assess for pulmonary or CNS involvement.
First-line treatments include amphotericin B and flucytosine, followed by maintenance therapy with fluconazole.
Immunocompromised patients are at a higher risk for severe disease and complications, making accurate documentation of their status critical for treatment planning.
